NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS) — Perfil da empresa, notícias e dados financeiros
NewAmsterdam Pharma develops innovative therapies for severe cardiometabolic diseases, focusing on improving patient outcomes.
NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Company (NASDAQ:NAMS) is a dynamic enterprise dedicated to developing innovative solutions in the healthcare sector. At its core, the company focuses on creating and advancing a portfolio of therapeutic products aimed at addressing severe cardiometabolic diseases, a realm where patient needs are continuously evolving and growing. NewAmsterdam Pharma is committed to improving clinical outcomes and enhancing the quality of life for patients around the globe through its dedicated research, development, and commercialization efforts. The company's projects range from early-stage discovery to late-stage development, underlining its objective to deliver breakthrough treatments that can significantly impact public health. NewAmsterdam Pharma operates with a vision to become a pivotal player in transforming the management of cardiometabolic disorders, leveraging cutting-edge science and strategic partnerships to achieve its goals.
Resumo
Operações
Produtos e/ou serviços de NewAmsterdam Pharma Company N.V.
- Developing a novel oral cholesteryl ester transfer protein inhibitor for reducing cardiovascular risk.
- Focusing on therapies for metabolic and cardiovascular diseases.
- Advancing a pipeline of proprietary compounds for dyslipidemia management.
- Researching innovative approaches to treat non-alcoholic steatohepatitis (NASH).
- Exploring potential treatments for familial hypercholesterolemia.
- Expanding into the development of solutions for reducing triglyceride levels.
equipe executiva do NewAmsterdam Pharma Company N.V.
- Michael Harvey DavidsonCEO, President & Executive Director
- Johannes Jacob Pieter KasteleinFounder, Chief Scientific Officer, Member of Executive Board & Director
- Mayur Amrat SomaiyaChief Financial Officer
- Robert W. GunningPrincipal Accounting Officer, VP & Controller
- Matthew PhilippeExecutive VP & Head of Investor Relations
- Michael F. MarinoChief Legal Officer & Corporate Secretary
- Chris DeluzioExecutive Vice President of Sales Enterprise Operations
- Maryellen McQuadeChief People Officer
- Juliette AudetChief Strategy & Business Officer
- Marc DitmarschChief Development Officer
Últimas notícias sobre a NewAmsterdam Pharma Company N.V.
Principais indicadores financeiros
Resultados divulgados pela NewAmsterdam Pharma Company N.V., em USD.
- Cap. de mercado
- 2,5 bi
- Receita (TTM)
- 7,1 mi
- P/L
- —
- LPA (diluído, TTM)
- -2.2
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 22,5 mi | -225,7 mi | -203,8 mi | |
| 45,6 mi | -176,3 mi | -241,6 mi | |
| 14,1 mi | -183 mi | -176,9 mi | |
| 102,7 mi | -3,6 mi | -22,6 mi |